摘要
目的:探究终末期肾脏病伴继发性甲状旁腺功能亢进症患者生化指标的特征。方法:选取2015年6月-2016年6月在本院治疗的100例慢性肾病伴继发性甲状旁腺功能亢进症患者为研究组,100例健康人为对照组,其中研究组进行透析治疗。观察研究组不同年龄段患者的钙化情况,比较研究组治疗3、6、12个月的血钙、甲状旁腺素、血磷水平,比较两组实验室检查结果(血清尿素、总胆固醇、ALP、cFGF-23、iPTH)。结果:不同年龄段患者钙化率比较差异有统计学意义(P<0.05);研究组血清尿素、总胆固醇、ALP、cFGF-23及iPTH水平均高于对照组,比较差异均有统计学意义(P<0.05);研究组不同治疗时间的血钙、甲状旁腺素以及血磷水平比较,差异均有统计学意义(P<0.05),其中治疗3、6、12个月的血钙、甲状旁腺素、血磷水平均呈下降趋势。结论:晚期肾病伴继发性甲状旁腺功能亢进症患者的血清尿素、总胆固醇、ALP、cFGF-23以及iPTH的指标均较高,在临床上有极其重要的意义,且患者的年龄越大,钙化率越高。
Objective:To explore the biochemical characteristics and vascular calcification of patients with end-stage renal disease and secondary hyperparathyroidism.Method:A total of 100 patients with chronic nephropathy and secondary hyperparathyroidism treated in our hospital from June 2015 to June 2016 were selected as study group and 100 healthy persons as control group.The study group was treated with dialysis.The calcification of patients of different age groups in study group was compared.The levels of serum calcium,parathyroid hormone and phosphorus after 3,6 and 12 months of treatment in study group were compared.The results of laboratory tests(serum urea,total cholesterol,ALP,cFGF-23,iPTH)between two groups were compared.Result:The calcification of patients of different age groups in study group was compared,the difference was statistically significant(P<0.05).The levels of serum urea,total cholesterol,ALP,cFGF-23 and iPTH in study group were higher than those of control group(P<0.05).The levels of serum calcium,parathyroid hormone and blood phosphorus in study group at different treatment time were compared,the differences were statistically significant(P<0.05),and blood calcium,parathyroid hormone and blood phosphorus levels decreased 3,6 and 12 months after treatment.Conclusion:Serum levels of urea,total cholesterol,ALP,cFGE-23 and iPTH were higher in end-stage renal disease patients with secondary hyperparathyroidism than those of control group,has important clinical significance,and the older,the higher the rate of calcification.
作者
朱峰
王琳
辛明徽
刘强强
ZHU Feng;WANG Lin;XIN Minghui(Xinhua Hospital of Dalian University,Dalian 116001,China)
出处
《中国医学创新》
CAS
2019年第6期105-108,共4页
Medical Innovation of China
基金
大连市卫生科研课题(1611095)